JP2017007956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017007956A5 JP2017007956A5 JP2015122399A JP2015122399A JP2017007956A5 JP 2017007956 A5 JP2017007956 A5 JP 2017007956A5 JP 2015122399 A JP2015122399 A JP 2015122399A JP 2015122399 A JP2015122399 A JP 2015122399A JP 2017007956 A5 JP2017007956 A5 JP 2017007956A5
- Authority
- JP
- Japan
- Prior art keywords
- interleukin
- therapeutic
- reducing agent
- binding
- resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100033499 Interleukin-34 Human genes 0.000 claims 4
- 101710181549 Interleukin-34 Proteins 0.000 claims 4
- 239000003638 chemical reducing agent Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015122399A JP6621252B2 (ja) | 2015-06-17 | 2015-06-17 | 治療耐性がんに対する治療耐性低減剤 |
| US15/736,203 US20180193453A1 (en) | 2015-06-17 | 2016-06-16 | Treatment-resistance reducing agent for treatment-resistant cancer |
| PCT/JP2016/067906 WO2016204216A1 (ja) | 2015-06-17 | 2016-06-16 | 治療耐性がんに対する治療耐性低減剤 |
| EP16811690.3A EP3311840B1 (en) | 2015-06-17 | 2016-06-16 | Treatment-resistance reducing agent for treatment-resistant cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015122399A JP6621252B2 (ja) | 2015-06-17 | 2015-06-17 | 治療耐性がんに対する治療耐性低減剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017007956A JP2017007956A (ja) | 2017-01-12 |
| JP2017007956A5 true JP2017007956A5 (cg-RX-API-DMAC7.html) | 2018-08-02 |
| JP6621252B2 JP6621252B2 (ja) | 2019-12-18 |
Family
ID=57545648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015122399A Active JP6621252B2 (ja) | 2015-06-17 | 2015-06-17 | 治療耐性がんに対する治療耐性低減剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180193453A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3311840B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6621252B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016204216A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6356317B1 (ja) * | 2017-06-05 | 2018-07-11 | 国立大学法人北海道大学 | 多発性骨髄腫患者の医薬への応答性を判定する方法、並びに多発性骨髄腫患者における骨病変の予防及び／又は治療のための医薬 |
| WO2020027217A1 (ja) * | 2018-07-31 | 2020-02-06 | 国立大学法人北海道大学 | がんの治療及び／又は予防のための医薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| CA2797399C (en) * | 2010-05-04 | 2021-03-02 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| ES2618828T3 (es) * | 2011-07-18 | 2017-06-22 | The University Of Melbourne | Uso de antagonistas de c-Fms |
| CN104093740B (zh) * | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| JP6827928B2 (ja) * | 2014-12-19 | 2021-02-10 | ユニヴェルシテ・ドゥ・ナント | 抗ｉｌ−３４抗体 |
| TWI725966B (zh) * | 2015-04-13 | 2021-05-01 | 戊瑞治療有限公司 | 癌症組合療法 |
-
2015
- 2015-06-17 JP JP2015122399A patent/JP6621252B2/ja active Active
-
2016
- 2016-06-16 EP EP16811690.3A patent/EP3311840B1/en active Active
- 2016-06-16 US US15/736,203 patent/US20180193453A1/en not_active Abandoned
- 2016-06-16 WO PCT/JP2016/067906 patent/WO2016204216A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400024I1 (hu) | A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| MY187540A (en) | Compounds active towards bromodomains | |
| PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| WO2014145642A3 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| MX393818B (es) | Terapias de combinación para el tratamiento de cáncer. | |
| WO2015048689A8 (en) | Inhibitors of bruton's tyrosine kinase | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| EP4382164A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| MX2016009332A (es) | Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo. | |
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| HK1216083A1 (zh) | 经动脉的药物递送 | |
| WO2014153030A3 (en) | Methods of treating cancer and preventing cancer drug resistance | |
| WO2015009726A3 (en) | Medical uses of cd38 agonists | |
| BR112017016503A2 (pt) | conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo | |
| SI3069720T1 (sl) | Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni | |
| BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| LT3168214T (lt) | Pakeisti 2-tiokso-imidazolidin-4-onai ir jų spiro analogai, aktyvi priešvėžinė sudedamoji dalis, farmacinė kompozicija, medicininis paruošimas, prostatos vėžio gydymo būdas | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| SG11201605868XA (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| MX2019015527A (es) | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. | |
| JP2016183163A5 (cg-RX-API-DMAC7.html) |